What Values Should Count in HTA for New Medicines under Value Based Pricing in the UK

@inproceedings{Orr2011WhatVS,
  title={What Values Should Count in HTA for New Medicines under Value Based Pricing in the UK},
  author={Shepley Orr and Jonathan Samuel Wolff and Steven Morris},
  year={2011}
}
and the Health Economics and Outcomes Research teams at Novartis UK for their comments at presentations of earlier versions of this paper. We are especially grateful to participants at a one‐day workshop held at UCL on this report for their effort and numerous insightful comments: 

Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Incorporating Multiple Criteria in HTA: Methods and Processes. London: Office of Health Economics

  • N Devlin, J Sussex
  • Incorporating Multiple Criteria in HTA: Methods…
  • 2011
1 Excerpt

Well‐being and disadvantage. What do people think?

  • G Brock, P Mckibbin
  • International Journal of Ethics
  • 2011

The NHS Outcomes Framework 2011‐12. London: Department of Health

  • Department of Health
  • 2010

Appraising Life‐Extending, End of Life Treatments

  • National Institute of Health and Clinical…
  • 2009

Similar Papers

Loading similar papers…